When Your Genes Had to Choose Which Disease to Fight - David Reich
Why It Matters
Ancient selection on disease‑related genes shapes present‑day susceptibility, guiding medical research and public‑health policy.
Key Takeaways
- •TB‑risk variant surged to ~10% frequency 6‑8k years ago.
- •Frequency sharply declined over the past 3,000 years.
- •Selection likely shifted from protection against another disease to TB susceptibility.
- •Immune system trade‑offs can increase autoimmunity risk in populations.
- •Genetic evidence reveals historic disease pressures shaping modern health.
Summary
The video features geneticist David Reich explaining how a single genetic variant associated with severe tuberculosis rose dramatically in ancient human populations and later receded. He outlines that the allele climbed to roughly 9‑10% frequency between 8,000 and 6,000 years ago, then dropped sharply over the last three millennia, a pattern that unmistakably signals natural selection.
Reich argues the rise likely reflected a protective advantage against a disease that pre‑dated widespread tuberculosis, while the subsequent decline coincides with TB becoming endemic, turning the same allele into a liability. He emphasizes the immune system’s “army‑like” nature, where adaptations that fend off one pathogen can impair defenses against another, potentially heightening auto‑immune disorders.
A memorable quote from Reich underscores this trade‑off: “The immune system is basically an army sitting in your body… optimized to attack malaria, but the same optimization makes it less optimal to attack some other disease.” He cites examples such as increased risk for multiple sclerosis or rheumatoid arthritis linked to the same genetic configuration.
The findings illustrate how historic disease pressures have left a lasting imprint on modern genetic risk profiles, informing public‑health strategies, drug development, and personalized medicine by reminding us that today’s health challenges are rooted in ancient evolutionary battles.
Comments
Want to join the conversation?
Loading comments...